Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249557 | 0.89 | GRM2 (0.42) | GRM2 | |
| SCHEMBL10252883 | 0.87 | GRM2 (0.44) | GRM2 | |
| SCHEMBL2038613 | 0.86 | GRM2 (0.38) | GRM2 | |
| SCHEMBL10249357 | 0.84 | — | — | |
| SCHEMBL84468 | 0.84 | — | — | |
| SCHEMBL10151433 | 0.84 | — | — | |
| SCHEMBL11886636 | 0.82 | GRM2 (0.44) | GRM2 | |
| SCHEMBL10249502 | 0.82 | GRM2 (0.44) | GRM2 | |
| SCHEMBL9743036 | 0.81 | GRM2 (0.36) | GRM2 | |
| SCHEMBL9743154 | 0.81 | GRM2 (0.36) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915813-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | GRM2 3994/4885IRAK4 1717/4885 |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | GRM2 4516/4885IRAK4 3856/4885 |
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | CYP3A5, GDI2, HDAC5 | GRM2 1832/4885IRAK4 4605/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | GRM2 2554/4885IRAK4 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.